Elsebet Ostergaard Nielsen

This inventor holds 27 USPTO granted patents and 5 published patent applications, plus 5 CIPO patents and 2 EPO patents, primarily in Neurotransmitter Inhibitors. Top assignees: Neurosearch A/s, Aniona Aps. Active years: 1994-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Elsebet Ostergaard Nielsen. Retrieved from https://idiyas.com/inventor/elsebet-ostergaard-nielsen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 27 (Patent Applications = 5)

% Patents Active = 44.4

CIPO Patents = 5 (Patent Applications = 39)

EPO Patents = 2

Average Co-Inventor Count = 4.1

ph-index = 4

Forward Citations = 77(Granted Patents)

Location History:

Kobenhavn K., DK (2004)
Kobenhaven, DK (2004)
Kobenhaven K, DK (2006)
Copenhagen, DK (1994 - 2007)
Ballerup, DK (2002 - 2008)
København K, DK (2010 - 2011)
København, DK (2011 - 2013)
Kobenhavn K, DK (2006 - 2015)

Company Filing History:

Years Active: 1994-2015

Loading Chart...

Areas of Expertise:

Chromen-2-One Derivatives

Monoamine Neurotransmitter

Re-Uptake Inhibitors

Nicotinic Acetylcholine

Receptor Ligands

Diazabicyclo Compounds

Dopamine D4 Antagonists

Imidazole Compounds

Cholinergic Ligands

Medical Use

Heteroaryl Derivatives

Pharmaceutical Applications

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9133184 - Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors (2015-09-15),

2. 8410271 - Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors (2013-04-02),

3. 8343960 - 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use (2013-01-01),

4. 8110586 - 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors (2012-02-07),

5. 8049012 - 3-aza-spiro[5.5]undecane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors (2011-11-01),

6. 7989470 - 3,8-substituted 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors (2011-08-02),

7. 7943630 - 3,9-diaza-spiro[5.5]undecane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors (2011-05-17),

8. 7935695 - 1,4-diaza-bicyclo[3.2.2]nonyl heteroaryl derivatives useful as nicotinic acetylcholine receptor ligands (2011-05-03),

9. 7855208 - 3, 9-diazabicyclo(3.3.1)non-3-yl-aryl methanone derivatives as nicotinic acetylcholine receptor agonists (2010-12-21),

10. 7329754 - 2,5-diazabicyclo[2.2.1]heptane derivatives (2008-02-12),

11. 7314870 - Compounds, their preparation and use (2008-01-01),

12. 7282494 - Heteroaryl diazacycloalkanes, their preparation and use (2007-10-16),

13. 7064118 - Heteroaryl diazacycloalkanes, their preparation and use (2006-06-20),

14. 7045522 - 8-Azabicyclo[3.2.1]oct-2-ene and -octane derivatives technical field (2006-05-16),

15. 6964972 - 8-Azabicyclo(3,2,1)oct-2 ene and octane derivatives as cholinergic ligands at nicotinic ACh receptors (2005-11-15),

Title: The Innovative Mind of Elsebet Ostergaard Nielsen

Introduction

Elsebet Ostergaard Nielsen, a prominent inventor based in København, DK, has made significant contributions to the field of pharmaceuticals with an impressive portfolio of 27 patents. Her work primarily focuses on chromen-2-one derivatives, paving the way for potential breakthroughs in the treatment of neurological disorders.

Latest Patents

Among her latest contributions, Elsebet has developed novel chromen-2-one derivatives that serve as monoamine neurotransmitter re-uptake inhibitors. One patent application discloses innovative compounds known as (8-aza-bicyclo[3.2.1]oct-3-yloxy)-chromen-2-one derivatives, highlighting their efficacy in therapeutic applications. These compounds not only demonstrate potential for medical use, but they are also included in pharmaceutical compositions aimed at improving patient outcomes in therapies targeting mental health and other neurological conditions.

Career Highlights

Elsebet has had a notable career with several reputable companies in the pharmaceutical sector. She has worked at Neurosearch A/S and Aniona ApS, where her expertise has significantly enhanced research and development efforts. Her innovative mindset and dedication to her work have driven her to achieve remarkable accomplishments in her field.

Collaborations

Throughout her professional journey, Elsebet has collaborated with various distinguished individuals, including her coworkers Dan Peters and Gunnar M Olsen. These partnerships have likely fostered a rich environment for creative problem-solving and knowledge exchange, leading to groundbreaking innovations.

Conclusion

With her remarkable track record of patents and contributions to neurology research, Elsebet Ostergaard Nielsen exemplifies the spirit of innovation. Her ongoing work continues to inspire the scientific community and promises to leave a lasting impact on pharmaceutical advancements.

Profile summary based on public USPTO records.